Article thumbnail

Modulation of Acetylation: Creating a Pro-survival and Anti-Inflammatory Phenotype in Lethal Hemorrhagic and Septic Shock

By Yongqing Li and Hasan B. Alam


Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in histone and nonhistone proteins and in regulating fundamental cellular activities. In this paper we review and discuss intriguing recent developments in the use of histone deacetylase inhibitors (HDACIs) to combat some critical conditions in an animal model of hemorrhagic and septic shock. HDACIs have neuroprotective, cardioprotective, renal-protective, and anti-inflammatory properties; survival improvements have been significantly shown in these models. We discuss the targets and mechanisms underlying these effects of HDACIs and comment on the potential new clinical applications for these agents in the future. This paper highlights the emerging roles of HDACIs as acetylation modulators in models of hemorrhagic and septic shock and explains some contradictions encountered in previous studies

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1995). A .B .P e i t z m a n ,B .G .H a r b r e c h t ,A .O .U d e k w u ,T .R .B i l l i a r
  2. (2005). A .R .S t a n k i e w i c z ,G .L a c h a p e l l e
  3. (2009). A l a m ,F .S h u j a ,M .U .B u t te ta l . ,“ S u r v i v i n gb l o o dl o s s without blood transfusion in a swine poly-trauma model,”
  4. (2006). a r a c o ,T .P a n c a n i ,L .F o r m e n t i n ie ta l . ,“ P h a r m a c o -logical inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain,”
  5. (2006). a r e ya n dN .B .L aT h a n g u e ,“ H i s t o n ed e a c e t y l a s e inhibitors: gathering pace,”
  6. (2009). a r i n o v a ,M .R e n ,J .R .W e n d l a n de ta l . ,“ V a l p r o i ca c i d induces functional heat-shock protein 70 via class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation,”
  7. (2008). a r u m o ,K .H i s h i k a w a ,M .Y o s h i k a w a ,a n dT .F u j i t a , “Epigenetic regulation of BMP7 in the regenerative response to ischemia,” J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y ,
  8. (2009). A.A.LaneandB.A.Chabner,“Histonedeacetylaseinhibitors in cancer therapy,”
  9. (2005). A.J.Kim,Y.Shi,R.C.Austin,andG.H.Werstuck,“Valproate protects cells fom ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3,”
  10. (2007). A.M.Winter-VannandG.L.Johnson,“Integrated activation of MAP3Ks balances cell fate in response to stress,”
  11. (2008). Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling,”
  12. (2002). Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB,”
  13. (2008). Acetylation: a novel method for modulation of the immune response following trauma/hemorrhageandinflammatorysecondhitinanimals and humans,”
  14. (2006). Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis,”
  15. (2006). Akt2 regulates cardiac metabolism and cardiomyocyte survival,”
  16. (2010). Altered adherent leukocyte profile on biomaterials
  17. (2009). Anti-inflammatory effect of trichostatin-A on murine bone marrow-derived macrophages,”
  18. (1998). attel¨ a,D.Wissing,K.Kokholm,T.Kallunki,andM.Egeblad, “Hsp7O exerts its anti-apoptotic function downstream of caspase-3-like proteases,”
  19. (2000). B.B.Wolf,K.Cainetal.,“Heat-shockprotein70 inhibits apoptosis by preventing recruitment ofprocaspase-9 to the
  20. (2003). Br` e s ,R .W .M .N ge ta l . ,“ P o s t - a c t i v a t i o n turn-off of NF-κB-dependent transcription is regulated by acetylation of p65,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
  21. (2003). C h a m p i o n ,R .F .B e l l a m y ,C .P .R o b e r t s ,a n dA .L e p -paniemi, “A profile of combatinjury,”
  22. (2001). C h a n g ,H .M .H s i e h -
  23. (2006). Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation,”
  24. (2004). Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth
  25. (1968). Chemical studies of histone acetylation. The distribution of epsilonN-acetyllysine in calf thymus histones,”
  26. (2005). Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene,”
  27. (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy,”
  28. (2002). Collette et al.,“Synergisticactivation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies,”
  29. (2006). D e i t c h ,D .X u ,a n dV .L .K a i s e r ,“ R o l eo ft h eg u ti nt h e development of injury- and shock induced SIRS and MODS: the gut-lymph hypothesis, a review,” Frontiers in Bioscience,
  30. (2007). DAMPs, PAMPs and alarmins:all we need to know about danger,”
  31. (1998). de la Pompa et al., “Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor
  32. (2010). Debosch et al., “TRB3 function in cardiac endoplasmic reticulum stress,”
  33. (1998). Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by Trichostatin A and butyrate,”
  34. (2003). Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitorsofclassIIahistonedeacetylasehomologue HD1-A,”
  35. Domain-selective small-molecule inhibitor ofhistonedeacetylase 6(HDAC6)-mediated tubulin deacetylation,”
  36. (2005). Drug insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid,”
  37. (2010). Dual role of heat shock proteins as regulators of apoptosis and innate immunity,”
  38. (2003). E.H ockly ,V .M.Ric hon,B.W oodmanetal.,“ Suber oylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease,”
  39. (1995). Early neutrophil sequestration after injury: a pathogenic mechanism for multiple organ failure,”
  40. (2005). Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis,”
  41. Epigenetics in anoxia tolerance: a role for histone deacetylases,” Molecular and Cellular Biochemistry.
  42. (2005). Epithelialbarrierdysfunction: a unifying theme to explain thepathogenesis ofmultiple organ dysfunction atthe cellularlevel,”
  43. (2008). Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway,”
  44. (2009). Explorative study on isoform-selective histone deacetylase inhibitors,”
  45. F u k u d o m e ,A .R .K o c h a n e k ,Y .L ie ta l . ,“ P h a r m a c o l o g i c resuscitation promotes survival and attenuates hemorrhageinduced activation of extracellular signal-regulated kinase 1/2,” Journal of Surgical Research.
  46. (2007). Free radicals and antioxidants in normal physiological functions and human disease,”
  47. (2010). Function and regulation of the mitochondrial Sirtuin isoform
  48. (1999). Georgescu et al., “Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association,”Cell,
  49. (2001). H a s s o u n ,B .C .K o n e
  50. (2009). h u i j l s ,J .J .D eH a a n ,J .P .M .D e r i k xe ta l . ,“ I n t e s t i n a l cytoskeleton degradation precedes tight junction lossfollowing hemorrhagic shock,”
  51. (2009). h u j a ,M .T a b b a r a ,Y .L ie ta l . ,“ P r o f o u n dh y p o t h e r m i a decreases cardiac apoptosis through Akt survival pathway,”
  52. (2005). H.Ryu,K.Smith,S.I.Cameloetal.,“Sodiumphenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice,”
  53. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis,”
  54. (2009). HDAC expression and clinical prognosis in humanmalignancies,”CancerLetters,vol.280,no.2,pp.168– 176,
  55. (2009). Heat shock proteins and immune system,”
  56. (1988). Hemorrhagic shock induces bacterial translocation from the gut,”
  57. (2008). Hepatic insulin resistance induced by prenatal alcohol exposure is associated with reduced PTEN and TRB3 acetylation in adult rat offspring,”
  58. (2008). Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock,”
  59. (2004). Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor2 activation and represses TNF gene expression,”
  60. (2001). Histone deacetylase as a therapeutic target,”
  61. (2007). Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver,”
  62. (2008). Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice,”
  63. (2003). Histone deacetylase inhibitionbysodium butyrate chemotherapy amelioratesthe neurodegenerative phenotype in Huntington’s disease mice,”
  64. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in
  65. (2010). Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis,”
  66. (2003). Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway,”
  67. (2001). Histone deacetylase inhibitors reduce polyglutamine toxicity,”
  68. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents,”
  69. (2005). Histone deacetylase inhibitors: new drugs forthe treatment of inflammatorydiseases?”Drug Discovery Today,
  70. (2007). Histone deacetylase inhibitors: overview and perspectives,”
  71. (2000). Histone deacetylase interacts directly with DNA topoisomerase II,”
  72. (2010). Histone deacetylase-3 activation promotes tumor necrosis factor-α (TNF-α) expression in cardiomyocytes during lipopolysaccharidestimulation,”Journal of
  73. (2009). Histone deacetylases augmentcytokineinductionoftheiNOS gene,”Journal of the American SocietyofNephrology,vol.13,no.8,pp.
  74. (2004). hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOPinduced apoptosis by inhibiting translocation
  75. (2008). Hwan et al., “Histone deacetylase inhibitor KBH-A42 inhibits cytokine production
  76. (2008). i ,B .L i u ,E .A .S a i l h a m e re ta l . ,“ C e l lp r o t e c t i v e mechanism of valproic acid in lethal hemorrhagic shock,”
  77. (2008). i ,Z .Y u a n ,B .L i ue ta l . ,“ P r e v e n t i o no fh y p o x i a - i n d u c e d neuronal apoptosis through histone deacetylase inhibition,”
  78. (2003). i s h i m o t o ,K .H a m a d a ,M .S a u n d e r se ta l . ,“ P h y s i o l o g i c a l functions of Pten
  79. (2010). Identification of a novel potential biomarker in a model of hemorrhagic shock and valproic acid treatment,”
  80. (2008). Inhibition of histone deacetylation protects wildtype but not gelsolindeficient mice from ischemic brain injury,”
  81. (1997). Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation,” Cytokine,v o l .9 ,n o .1 ,p p .
  82. (2007). Integrating cell-signalling pathways with NFκB andIKKfunction,”Nature Reviews MolecularCellBiology,
  83. (2003). K.Du,S.Herzig,R.N.Kulkarni,andM.Montminy,“TRB3:a tribbles homolog that inhibits Akt/PKB activation by insulin in liver,”
  84. (2003). Kemp, andA.B.P.VanKuilenburg,“Histonedeacetylases (HDACs): characterization of the classical
  85. (2009). Kr¨ amer, “Acetylation of non-histone proteins modulates cellular signalling at multiple levels,”
  86. (2006). LPS regulates proinflammatorygeneexpressioninmacrophagesbyaltering histone deacetylase expression,”
  87. (2008). M o l l e n ,R .M .L e v y ,J .M .P r i n c ee ta l . ,“ S y s t e m i c inflammation and end organ damage following trauma involves functional TLR4 signaling in both bone marrowderived cells and parenchymal cells,”
  88. M.Uldry et al.,“Suppression ofreactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators,”
  89. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating
  90. (2002). Min,“Regulation oflifespan by histone deacetylase,”
  91. (2004). Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,”
  92. (2001). Molecular mechanisms in the early phase of hemorrhagic shock,”
  93. (1992). Multiple organ failure: pathophysiology and potential future therapy,”
  94. (2011). N.Zacharias,E.A.Sailhamer,Y.Lietal.,“Histonedeacetylase inhibitors prevent apoptosis following lethal hemorrhagic shockin rodent kidney cells,”
  95. (2007). New insights into PTEN,”
  96. (1999). o l l o c h ,V .L .G a b a i ,S .R i t s ,a n dM .Y .S h e r m a n ,“ A T P a s e activity of the heat shock protein Hsp72 is dispensable for its effects on dephosphorylation of stress kinase JNK and on14
  97. (2006). o n z a l e s ,H .C h e n ,R .M u n u v ee ta l . ,“ V a l p r o i ca c i dp r e -vents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones,”
  98. (2002). P a r k ,S .G .C h o ,C .K .K i me ta l . ,“ H e a ts h o c kp r o t e i n Hsp72 is a negative regulator of apoptosis signal-regulating kinase 1,” Molecular and Cellular Biology,
  99. (2002). p38-dependent markingofinflammatorygenes forincreased NF-κBr e c r u i t m e n t ,
  100. (2010). Pharmacological resuscitation attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in rodent model,”
  101. (2003). Potentiation of tumor necrosis factor-induced NF-κBa c t i v a t i o nb yd e a c e t y l a s e inhibitors is associated with a delayed cytoplasmic reappearance of IκBα,” Molecular and Cellular Biology,
  102. (2009). Protective effect of suberoylanilide hydroxamic acid against lps-induced septic shock in rodents,”
  103. (2009). Protective effects of trichostatin A on liver injury in septic mice,”
  104. (1999). Protein-damaging stresses activate cJun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72,” Molecular and Cellular Biology,
  105. (2003). Putting the brakes on insulin signaling,” The New England
  106. (2000). Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization,”
  107. Regulation of Inducible Nitric Oxide Synthase Expression by p300 and p50
  108. (2003). Regulation of microglial inflammatory response by histone deacetylase inhibitors,”
  109. (2009). Regulation of the inducible nuclear dualspecificity phosphatase
  110. (2001). Role of the gut lymphatic system in multiple organ failure,” Current Opinion
  111. (2004). sepsis, and the regulation of Toll-like receptor responses,”
  112. (2004). Shaping the nuclear action of NF-κB,”
  113. (2008). Surviving blood loss without fluid resuscitation,”
  114. (2010). Surviving lethal septic shockwithoutfluidresuscitationinarodent model,”Surgery,
  115. (1997). Synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier,”
  116. (2004). t i l e s ,M .G r o s z e r ,S .W a n g ,J .J i a o ,a n dH
  117. (2007). Taye et al., “Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy,”
  118. (2000). The chaperone function of hsp70 is required for protection against stressinduced apoptosis,”
  119. The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation
  120. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-bindingprotein-2,anddown-regulates thioredoxin,”
  121. (2002). The histone deacetylase inhibitor trichostatin A blocks progesteronereceptor-mediated transactivationofthemouse mammary tumor virus promoter in vivo,”
  122. (2000). The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line,”
  123. The nuclear factor-κB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter,”
  124. (1999). The nucleosomal responseJournal of Biomedicine and Biotechnology 15 associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histoneH3/HMG-14 kinase,”The
  125. (2001). The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC)
  126. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease,”
  127. The Sp1-like protein BTEB3 inhibits transcription via the basic transcription element box by interacting with mSin3A and HDAC-1 co-repressors and competing with Sp1,”
  128. (2001). The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
  129. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate,”
  130. (2002). The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinaseC,”J o u r n a lo fB i o l o gi c a lC h em i s try ,vol.277,no.35,pp. 31585–31592,
  131. (2000). The β-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3’-kinase,”
  132. (2007). Thioredoxin and related molecules—frombiologytohealthanddisease,”Antioxidants and Redox Signaling,
  133. (2003). Transcriptional abnormalities in Huntington disease,”
  134. (2000). Transcriptional dysregulation in Huntington’s disease,”
  135. (2005). Transcriptional therapy with the histone deacetylase inhibitor trichostatin
  136. (2003). u n ge ta l . ,“ I d e n t i fi c a t i o no fn o v e l isoform-selective inhibitors within class I histone deacetylases,”
  137. (2003). Up-regulation of p300 binding and p50 acetylation in tumor necrosis factorα-induced cyclooxygenase-2 promoter activation,”
  138. (2006). W .K .C a v e n e e ,a n dF .B .F u r n a r i ,“
  139. (2005). Xu et al.,“Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors,”
  140. (1999). Yang et al., “RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins,”